Gastrointestinal neuroendocrine tumors treated with high dose octreotide-LAR: a systematic literature review - Wikidata - awgldk - TriplyDB

Gastrointestinal neuroendocrine tumors treated with high dose octreotide-LAR: a systematic literature review

Gastrointestinal neuroendocrine tumors treated with high dose octreotide-LAR: a systematic literature review

http://www.wikidata.org/entity/Q26866246

about

Somatostatin receptor expression indicates improved prognosis in gastroenteropancreatic neuroendocrine neoplasm, and octreotide long-acting release is effective and safe in Chinese patients with advanced gastroenteropancreatic neuroendocrine tumors.Prescription patterns of long-acting somatostatin analogues Octreotide LAR Dosage and Survival Among Elderly Patients With Distant-Stage Neuroendocrine Tumors.Somatostatin analogues according to Ki67 index in neuroendocrine tumours: an observational retrospective-prospective analysis from real life Update on management of midgut neuroendocrine tumors.Role of targeted agents in neuroendocrine tumors: Results from a meta-analysis.Refractory carcinoid syndrome: a review of treatment options.Somatostatin analogues in functioning gastroenteropancreatic neuroendocrine tumours: literature review, clinical recommendations and schedules.Cost reduction from resolution/improvement of carcinoid syndrome symptoms following treatment with above-standard dose of octreotide LAR.Treatment of symptomatic neuroendocrine tumor syndromes: recent advances and controversies.Telotristat ethyl: a new option for the management of carcinoid syndrome.Antiproliferative effect of somatostatin analogs in advanced gastro-entero-pancreatic neuroendocrine tumors: a systematic review and meta-analysis.The safety of available treatments options for neuroendocrine tumors.Escalated-dose somatostatin analogues for antiproliferative effect in GEPNETS: a systematic review.Effect of everolimus on the pharmacokinetics of octreotide long-acting repeatable in patients with advanced neuroendocrine tumors: An analysis of the randomized phase III RADIANT-2 trial.Comparing the Cost of Treatment with Octreotide Long-Acting Release versus Lanreotide in Patients with Metastatic Gastrointestinal Neuroendocrine Tumors.Peptides and Drug Delivery.Anti-tumoral effects of somatostatin analogs: a lesson from the CLARINET study.Carcinoid-syndrome: recent advances, current status and controversies.Practical management of toxicities associated with targeted therapies for advanced gastroenteropancreatic neuroendocrine tumors.A systematic review and meta-analysis of gastrointestinal events associated with nonoperative therapies for neuroendocrine tumors

P2860

Q33598860-4C521028-6428-46E0-85E2-CE7116CD8B59 Q33694027-CAFF75EA-BF51-4E68-8CD4-49A4B62DE377 Q36673485-2E08B293-20D6-45D0-9E0A-7C46C8D676E5 Q36905710-06A648E6-1C73-4B35-B9A9-C621847F884C Q37025143-4C657798-0155-4A40-9A53-FCF8D8ECC265 Q37282982-7FCBC1BE-E107-4812-B1CE-28F1EEF2749C Q37632161-AF724E29-7F76-45AD-8D9C-657901864174 Q38647297-8270704F-149D-4913-A32A-3C15AAB0B2C9 Q38754287-3C4AEF06-6615-4F50-B383-632571A3B957 Q38956091-3D3EF672-569A-42AB-99D8-35D7221F256D Q39000212-88861C1D-DC2B-435A-BDEF-F260BC87525A Q39237792-40A0DE7E-DA88-4A95-81DA-41B98DE76332 Q39433254-EDFF41D4-A120-499F-B6C5-93B5A958A240 Q39447034-3457425D-661B-49BF-BD8A-A1ADC4A4D7EF Q40403300-6B126D9E-0732-4992-8169-288BDE4D5B05 Q47094179-5358F4EF-DFFB-4178-A512-7E8CFD992C11 Q47590591-B1903E89-E1C1-4FB4-8BCB-629F6E3DF1FB Q47827757-CAB691B2-7002-4262-83AF-88774B70247A Q50094023-FB14A8CF-4790-4D76-B0ED-1B6205259BFF Q55502689-2BB03468-08CF-4907-B22B-71AD9A2A2FB9 Q59135219-472D5289-17A9-455A-93F8-E37D62A2FFBA

P2860

Gastrointestinal neuroendocrine tumors treated with high dose octreotide-LAR: a systematic literature review

http://www.wikidata.org/entity/Q26866246

description

2015 nî lūn-bûn

@nan

2015 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Gastrointestinal neuroendocrin ...... a systematic literature review

@ast

Gastrointestinal neuroendocrin ...... a systematic literature review

@en

Gastrointestinal neuroendocrin ...... a systematic literature review

@nl

type

label

Gastrointestinal neuroendocrin ...... a systematic literature review

@ast

Gastrointestinal neuroendocrin ...... a systematic literature review

@en

Gastrointestinal neuroendocrin ...... a systematic literature review

@nl

prefLabel

Gastrointestinal neuroendocrin ...... a systematic literature review

@ast

Gastrointestinal neuroendocrin ...... a systematic literature review

@en

Gastrointestinal neuroendocrin ...... a systematic literature review

@nl

P1433

Q26866246-4F201874-5837-4D9C-A642-87FD98C0E542

P1476

Q26866246-856CCAFB-FF10-4EC4-BC9D-C695A887CCF3

P2093

Q26866246-6597A37B-0578-4085-AB25-183A3462B32A

P2860

Q26866246-367FD880-4AED-4085-80FF-BBA1D43797A9

Q26866246-4AC542B8-D95E-4344-AF72-D59AAD92519E

Q26866246-5800B454-7382-4670-9A78-A14118A71647

Q26866246-59F5C730-16E2-4C37-A439-D0674407AFC7

Q26866246-6BDD26F5-B02A-46F6-A77A-90D866EBDCBD

Q26866246-7A04B208-B832-41D9-A81F-942F37E285AE

Q26866246-9172D099-7697-4AC5-A8DE-913CE817EC88

Q26866246-9ECA1403-5507-4521-A92C-C4C30258F44C

Q26866246-B9C8B70F-0071-4E17-9074-789028757977

Q26866246-CEB71B31-1EA4-426C-A31C-C2DD908F7A87

P304

Q26866246-3FBFBEA9-EF82-4751-BF12-D356D7CA88D0

P31

Q26866246-22BE328B-4ECA-42C0-83D0-AFD44B7FC32F

P356

Q26866246-F72860B6-00E0-4325-9E7E-DE462F81C192

P407

Q26866246-7B1DE839-2641-4D5F-BC5B-70D1EAB16015

P433

Q26866246-823F0D94-BAAA-404D-8658-33E69792ADE6

P478

Q26866246-B371706C-F5DF-48D4-8C54-5C311E9118BE

P577

Q26866246-2E4379F6-1B11-42E7-9D04-51ACD0CDDDAB

P698

Q26866246-85B12E90-79AB-46B0-B2AF-C57EDDF87F9D

P932

Q26866246-BA28FAB4-207A-4111-A28B-9ECBE0C6F291

P356

WJG.V21.I6.1945

P1433

World Journal of Gastroenterology

P1476

Gastrointestinal neuroendocrin ...... a systematic literature review

@en

P2093

Michael S Broder

http://www.w3.org/2001/XMLSchema#string

P2860

Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system

Understanding interobserver agreement: the kappa statistic

Above-Label Doses of Octreotide-LAR in Patients With Metastatic Small Intestinal Carcinoid Tumors.

NANETS consensus guidelines for the diagnosis of neuroendocrine tumor.

Evaluating the characteristics and the management of patients with neuroendocrine tumors receiving octreotide LAR during a 6-year period.

Safety review: dose optimization of somatostatin analogs in patients with acromegaly and neuroendocrine tumors.

Systemic treatment in unresectable metastatic well-differentiated carcinoid tumors: consensus results from a modified delphi process.

Somatostatin analogues: treatment of pituitary and neuroendocrine tumors.

High-dose octreotide acetate for management of gastroenteropancreatic neuroendocrine tumors.

Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group.

P304

1945-55

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3748/WJG.V21.I6.1945

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

21

http://www.w3.org/2001/XMLSchema#string

P577

2015-02-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25684964

http://www.w3.org/2001/XMLSchema#string

P932

4323475

http://www.w3.org/2001/XMLSchema#string